Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsTomoyuki IGAWA, Shinya ISHII, Atsuhiko MAEDA, Takashi NAKAI
Life of this patent
Estimating the term…
Abstract
The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
Claims13
An antigen-binding molecule having a KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4, of 2 or higher.
2-8. (canceled)
A method for improving the pharmacokinetics of an antigen-binding molecule, for increasing the number of times of antigen-binding for an antigen-binding molecule, for increasing the number of antigens that can be bound by an antigen-binding molecule, for dissociating within a cell an antigen from an extracellularly-bound antigen-binding molecule, for releasing an antigen-binding molecule, which has been bound to an antigen and internalized into a cell, in an antigen-free form to the outside of the cell, or for increasing the ability of an antigen-binding molecule to eliminate an antigen in plasma by impairing the antigen-binding activity of the antigen-binding molecule at pH 5.8 as compared to that at pH 7.4.
10-14. (canceled)
16-17. (canceled)
A method for improving the pharmacokinetics of an antigen-binding molecule, for increasing the number of times of antigen-binding for an antigen-binding molecule, for increasing the number of antigens that can be bound by an antigen-binding molecule, for dissociating within a cell an antigen from an extracellularly-bound antigen-binding molecule, for releasing an antigen-binding molecule, which has been bound to an antigen and internalized into a cell, in an antigen-free form to the outside of the cell, or for increasing the ability of an antigen-binding molecule to eliminate an antigen in plasma by substituting at least one amino acid of the antigen-binding molecule with histidine, or inserting at least one histidine into the antigen-binding molecule.
19-23. (canceled)
28-50. (canceled)
Dependencies are inferred from the claim text.